1 / 6

U.S. General Anesthesia Drugs Market estimated worth 2 Billion USD by 2020

The U.S. general anesthesia drugs market is poised to reach USD 2.0 Billion by 2020 from USD 1.6 Billion in 2015, at a CAGR of 3.8% from 2015 to 2020.

dhruv13
Download Presentation

U.S. General Anesthesia Drugs Market estimated worth 2 Billion USD by 2020

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MarketsandMarkets Presents U.S. General Anesthesia Drugs Market to reach $2 Billion by 2020 http://www.marketsandmarkets.com/Market-Reports/cholesterol-testing-services-market-180941049.html

  2. This report "U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020", provides a detailed overview of the market for ketamine in the U.S., current market trends, supply chain, competitive analysis, market entry strategies, and revenue forecast. Browse: 42 market data tables 28 figures 114 pages and in-depth TOC on "U.S. General Anesthesia Drugs Market” Download The PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=713 The U.S. general anesthesia drugs market is poised to reach ~ USD 2.0 Billion by 2020 from USD 1.6 Billion in 2015, at a CAGR of 3.8% from 2015 to 2020. http://www.marketsandmarkets.com/Market-Reports/anesthesia-drugs-ketamine-market-713.html

  3. Factors such as rapid rise in aging population, rising prevalence of cardiovascular and respiratory system-related diseases, and rising number of emergency surgeries are driving the growth of the U.S. general anesthesia drugs market. Speak to Analyst@ http://www.marketsandmarkets.com/speaktoanalyst.asp?id=713 However, side effects associated with ketamine usage (such as elevation in blood pressure and heart rate, amnesia, respiratory depression, and hallucinations), regulatory issues, and lower compliance rates in comparison with other anesthetic drugs are likely to restrain the growth of this market. The market is segmented on the basis of molecule and route of administration. On the basis of molecules, the market is divided into Propofol, Benzodiazepine, Ketamine (S-(+)-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action. http://www.marketsandmarkets.com/Market-Reports/anesthesia-drugs-ketamine-market-713.html

  4. On the basis of route of administration, the U.S. general anesthesia drugs market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the U.S. general anesthesia drugs market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of this market. Major players operating in the U.S. general anesthesia drugs market are AstraZeneca plc (U.K.), Baxter International Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Eisai Co., Ltd. (Japan), Fresenius Se & Co. KGaA (Germany), Hospira, Inc. (U.S.), and Par Pharmaceutical Companies, Inc. (U.S.). http://www.marketsandmarkets.com/Market-Reports/anesthesia-drugs-ketamine-market-713.html

  5. About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.  http://www.marketsandmarkets.com/Market-Reports/anesthesia-drugs-ketamine-market-713.html

  6. Contact Us Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: 1-888-600-6441 Email: sales@marketsandmarkets.comMarketsandMarkets Bloghttp://www.marketsandmarkets.comhttp://twitter.com/marketsmarkets http://www.linkedin.com/company/marketsandmarkets

More Related